January 11, 2017
The Ministry of Health, Labor and Welfare (MHLW) on January 10 ordered a label revision for Celgene’s multiple myeloma med Revlimid (lenalidomide) to warn of the risk of hepatitis B virus reactivation. In its notification to the Federation of Pharmaceutical...read more